|Day Low/High||3.22 / 3.47|
|52 Wk Low/High||3.14 / 8.56|
There's every reason to think Pitney Bowes is once again primed for a major upturn.
With chart resistance in the $8-$10 area and no base pattern to point to, I would look for Pitney Bowes to trade sideways before resuming an upside move.
Who, out there in the health care sector, is safe?
Firms that adapted to hard times are now doing exponentially better.
Investors prep for details on tax reform, key corporate earnings and a decision on the new Federal Reserve Chairman.
Its ridiculously low multiple and well-covered dividend of nearly 6% make it an attractive value buy.
* Little happening (modest gain in the S&P Index), save the continued rotation mentioned this morning. * Sentiment is that new Chief of Staff John Kelly will bring some order into a disorganized and dysfunctional White House. * Busy morning for data...
PBI's low valuation, high yield and juicy option premiums get our stamp of approval.
Funds are unloading shares of these five big stocks -- but the timing looks suspect on a few of them.
The holidays can be a boon for small businesses, but they can also cause major headaches for those who need to ship to their customers.
Online marketplaces are becoming the de facto shopping destination for online shoppers.
Internet search engines and social media sites are increasingly driving global online shopping trends, according to a new survey conducted by Pitney Bowes.
Some companies have been able to survive and thrive in new environments.
Pitney Bowes closes above upper end of the bull flag pattern, the trade idea is in motion.
Former Nifty Fifty name Xerox has seen a rennaissance in 2013. Portfolio Manager David Peltier discusses if the stock can continue to run.
$2.1 billion. "One last thing." -- Lt. Columbo My mavens on the floor see $2.1 billion to buy on the close. Financials have $490 million to buy, energy $300 million to buy, consumer staples $300 million to buy and health care $250 million to buy. In...
David Peltier, Portfolio Manager of Stocks Under $10 and Jill Malandrino look at names that are high yield dividend plays, but are they worth a holding in your portfolio?